Review on Brain Metastases in HER2-positive Breast Cancer Patients

ZHOU Xia; DU Xianghui; QIU Guoqin

doi:10.3971/j.issn.1000-8578.2014.06.038

Cancer Research on Prevention and Treatment > 2014 > 41(06): 680-685. > DOI: 10.3971/j.issn.1000-8578.2014.06.038

ZHOU Xia, DU Xianghui, QIU Guoqin. Review on Brain Metastases in HER2-positive Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 680-685. DOI: 10.3971/j.issn.1000-8578.2014.06.038

Citation:

PDF (1118 KB)

Review on Brain Metastases in HER2-positive Breast Cancer Patients

Department of Radiation Oncology, Zhejiang Cancer Hospital,Hangzhou 310022,China

More Information

Received Date: January 19, 2014
Revised Date: March 22, 2014

Graphical Abstract

Abstract

Abstract

The widespread use of trastuzumab in recent years has led to a significant improvement in the survival of breast cancer patients with overexpressed human epidermal growth factor receptor-2(HER2-positive). However with improved systemic control and prolonged survival, the incidence of brain metastasis has increased. Brain metastasis, often in the setting of well-controlled extracranial disease, is proved to be an increasingly important and clinically challenging cause of morbidity and mortality in HER2-positive breast cancer patients. In this review, we will discuss the targeted therapies of HER2-positive brain metastasis and summarize information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention.
- HER2,
- Breast cancer,
- Brain metastases,
- Blood-brain barrier,
- Trastuzumab,
- Lapatinib

FullText(HTML)

References (37)

References

[1]	Barnholtz-Sloan JS,Sloan AE,Davis FG,et al.Incidence proportions of brain metastases in patients diagnosed(1973 to 2001) in the Metropolitan detroit cancer surveillance system[J].J Clin Oncol, 20 04,22(14):2865-72.
[2]	Wang XJ.Stategies and clinical pratctice of breast cancer medicine comprehensive treatment[M].Beijing:Tsinghua University Press(To be published).[王晓稼.乳腺癌内科综合治疗策略与临床实践[M].北京:清华大学出版社(待发表).]
[3]	Pestalozzi BC, Zahrieh D, Price KN，et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) [J]. Ann Oncol.2006, 17(6):935-44.
[4]	Gabos Z, Sinha R, Hanson J，et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer[J]. J Clin Oncol,2006,24(36):5658-63.
[5]	Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet,2007, 36 9(9555):29-36.
[6]	Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353??16):1673-84.
[7]	Olson EM, Abdel-Rasoul M, Maly J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab[J]. Ann Oncol, 2013,24(6):1526-33.
[8]	Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials[J]. Breast Cancer Res Treat, 2008,109(2):231-9.
[9]	Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her2-positive early breast cancer: a meta-analysis of published randomized trials[J]. BMC Cancer,2007, 7:153.
[10]	Dijkers EC, Oude Munnink TH,Kosterink JG,et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer[J]. Clin. Pharmacol Ther, 20 10, 87(5):586-92.
[11]	Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) [J]. Ann Oncol. 20 10,21(5):942-8.
[12]	Fidler IJ. The role of the organ microenvironment in brain metastasis[J]. Semin Cancer Biol.2011,21(2):107-12.
[13]	Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fl uid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier[J]. Anticancer Drugs,2007,18(1):23-8.
[14]	Hu J, Ljubimova JY, Inoue S,et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment effi cacy in mouse metastatic brain tumor models[J]. PLoS One, 2010, 5(4): e10108.
[15]	Kinoshita M, McDannold N, Jolesz FA, et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption[J]. Proc Natl Acad Sci U S A, 2006, 103(31):11719-23.
[16]	Joo KM, Park IH, Shin JY, et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases[J]. Mol Ther, 2009, 17(3):570-5.
[17]	Colozza M, Minenza E, Gori S, et al. Extended survival of a HER2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab[J]. Cancer Chemother Pharmacol,2009, 63(6):1157-9.
[18]	Liang K, Lu Y, Jin W, et al. Sensitization of breast cancer cells to radiation by trastuzumab[J]. Mol Cancer Ther, 2003, 2(11), 11 13-20.
[19]	Chargari C, Idrissi HR, Pierga JY, et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2010, 81(3): 631-6.
[20]	Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER[J]. Clin Cancer Res, 2011, 17(14):4834-43.
[21]	Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol,2008, 26(12): 19 93-9.
[22]	Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J].Clin Cancer Res, 2009, 15(4): 1452-9.
[23]	Sutherland S, Ashley S, Miles D, et al. Treatment of HER2- positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including effi cacy in brain metastases--the UK experience[J]. Br J Cancer,2010, 10 2(6):995-1002.
[24]	Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study[J].Lancet Oncol, 2013,14(1):64-71.
[25]	Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases[J]. Clin Cancer Res, 2010,16(1):269-78.
[26]	Lu Y-S, Chen W-W, Lin C-H,et al. Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy-Subgroup analysis of a multi-center phase II study.http://www.abstracts2view.com/sabcs13/view.php? nu=SABCS13L_182&terms=
[27]	Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer[J]. J Clin Oncol, 2010,28(8):1301-7.
[28]	Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer[J]. Br J Cancer, 2013,108(10):1985-93.
[29]	Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors[J]. J Clin Oncol,2010,28(25):3965-72.
[30]	Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone[J]. Int J Radiat Oncol Biol Phys, 2007,68(5):1388-95.
[31]	Wadasadawala T,Gupta S,Baqul V,et al. Brain metastases from breast cancer:management approach[J].J Cancer Res Ther,2007,3(3):157-65.
[32]	Rades D, Bohlen G, Lohynska R, et al. Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP) [J]. Strahlenther Onkol, 2007, 18 3(11): 631-6.
[33]	Chidel MA, Suh JH, Reddy CA, et al. Application of the recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases[J].Int J Radiat Oncol Biol Phys,2000,47(4):993-9.
[34]	Kondziolka D, Kano H, Harrison GL, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article[J]. J Neurosurg, 20 11,114(3):792-800.
[35]	Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death[J]. Int J Radiat Oncol Biol Phys, 2010,77(4):1134-9.
[36]	Cameron D, Casey M, Press M,et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat,2008, 112(3):533-43.
[37]	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00820 222.

[1]	LUO Yue, LI Yue, HU Jiaqi, YU Huibo, WANG Linfeng, HUA Baojin, LIU Rui. Clinical Characteristics and TCM Syndrome Patterns in 721 Female Patients with Pulmonary Nodules[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.2025.25.0159
[2]	YU Huibo, LI Yue, LUO Yue, LIU Hongyuan, ZHANG Xiyuan, HU Jiaqi, LIU Rui, HUA Baojin. Medication Rules of Professor Hua Baojin in Treatment of Subsolid Pulmonary Nodules Based on Data Mining[J]. Cancer Research on Prevention and Treatment, 2025, 52(8): 682-691. DOI: 10.3971/j.issn.1000-8578.2025.25.0051
[3]	LI Yue, HU Jiaqi, HU Yue, LEI Zehang, WANG Linfeng, LIU Rui, HUA Baojin. A Practical Randomized Controlled Study on Effectiveness of TCM Syndrome Differentiation Treatment for Subsolid Pulmonary Nodules[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 373-379. DOI: 10.3971/j.issn.1000-8578.2024.23.1110
[4]	WANG Yuanrong, ZHANG Liming, SONAM Daji, ZHU Yan, FAN Gentao, WANG Yicun, SHI Xin, WU Sujia, ZHOU Guangxin. Chest CT Imaging Features of Indeterminate Pulmonary Nodules and Outcomes in Patients with High-grade Soft Tissue Sarcoma: A Single-center Retrospective Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 99-103. DOI: 10.3971/j.issn.1000-8578.2024.23.0810
[5]	LIU Xuejiao, LI Bin, LI Yan, CHEN Si, LI Biqiang. Evaluation of Four Predictive Models for Identifying Malignancy of Solitary Pulmonary Nodules in Health Check-up Population[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 477-482. DOI: 10.3971/j.issn.1000-8578.2023.22.1209
[6]	WEI Ning, LIN Ruijiang, MA Minjie, CHEN Chang, HAN Biao. Relation Between Imaging Microfeatures of Artificial Intelligence-assisted Diagnosis System and Prognosis of Lung Adenocarcinomas Presented as Ground-glass Nodules[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 877-882. DOI: 10.3971/j.issn.1000-8578.2021.21.0255
[7]	ZHANG Zhenghua, CAI Yaqian, HAN Dan, ZHOU Xiaojun, HUANG Yilong, LI Junli. Pulmonary Nodule Screening and Qualitative Diagnosis Based on Deep Learning[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 283-287. DOI: 10.3971/j.issn.1000-8578.2020.19.1107
[8]	JING Jian, ZHANG Jing. Role of Pathology in Early Detection and Management of Lung Cancer-the Necessity and Feasibility of Small Biopsies in Targeted Lung Nodule in Current Clinical Practice[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 963-970. DOI: 10.3971/j.issn.1000-8578.2019.19.0900
[9]	LIAO Mei-yan, SUN Jun-mo, TIAN Zhi-xiong, ZHANG Zai-peng, QU Yan-juan, HU Hao, LUO Rui. Spiral CT Diagnostic Value in Pulmonary Nodule to Assess Growth and Malignancy Status[J]. Cancer Research on Prevention and Treatment, 2004, 31(10): 627-630. DOI: 10.3971/j.issn.1000-8578.2564
[10]	ZHAO Zhen jun, LIANG Chang hong, ZHANG Jin e, QIAO Sui xian, LUO Yao wu, HE Hui, RU Guang teng. Comprehensive Analysis of CT,MRI and PET for Solitary Pulmonary Nodules[J]. Cancer Research on Prevention and Treatment, 2004, 31(08): 485-488. DOI: 10.3971/j.issn.1000-8578.3180

Cited By

Get Citation

PDF

XML

Article views (1966) PDF downloads (1084)

Turn off MathJax

Article Contents

Abstract

References

Review on Brain Metastases in HER2-positive Breast Cancer Patients

Abstract

References

Related Articles

Catalog

Contact Us

Review on Brain Metastases in HER2-positive Breast Cancer Patients

Abstract

References

Related Articles

Catalog

Contact Us

Export File

Citation

Format

Content